Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Saved in:
| Title: | Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. |
|---|---|
| Authors: | Hilberink JR; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., van Zeventer IA; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., Chitu DA; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Pabst T; Department of Oncology, University Hospital, Inselspital, and University of Bern, Bern, Switzerland., Klein SK; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.; Department of Internal Medicine, Meander Hospital Amersfoort, Amersfoort, the Netherlands., Stussi G; Department of Hematology, Oncology Institute of Southern Switzerland, Ospedale Regionale, Bellinzona, Switzerland., Griskevicius L; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania., Valk PJM; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Cloos J; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., van de Loosdrecht AA; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Breems D; Department of Hematology, ZNA Stuivenberg/Middelheim, Antwerp, Belgium., van Lammeren-Venema D; Department of Hematology, Hagaziekenhuis, Den Haag, the Netherlands., Boersma R; Department of Hematology, Amphia Hospital, Breda, the Netherlands., Jongen-Lavrencic M; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Fehr M; Department of Medical oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Hoogendoorn M; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, the Netherlands., Manz MG; Department of Medical Oncology and Hematology, Universitätsspital Zurich, Zurich, Switzerland., Söhne M; Department of Hematology, Antonius Hospital, Nieuwegein, the Netherlands., van Marwijk Kooy R; Department of Hematology, Isala Hospital, Zwolle, the Netherlands., Deeren D; Department of Hematology, AZ Delta Roeselare, Roeselare, Belgium., van der Poel MWM; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Legdeur MC; Department of Hematology, Medical Spectrum Twente, Enschede, the Netherlands., Tick L; Department of hematology, Maxima Medical Center, Veldhoven, the Netherlands., Chalandon Y; Division of hematology, University Hospital Genève and Faculty of Medicine, University of Genève, Genève, Switzerland., Ammatuna E; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., Blum S; Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Löwenberg B; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Huls G; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands. g.huls@umcg.nl. |
| Corporate Authors: | Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK) |
| Source: | Blood cancer journal [Blood Cancer J] 2023 Jun 19; Vol. 13 (1), pp. 93. Date of Electronic Publication: 2023 Jun 19. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
